isoxazoles has been researched along with Carcinoma in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (11.11) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dong, W; Liu, J; Qin, Y; Sun, W; Wang, Z; Zhang, H; Zhang, T | 1 |
| Choi, MG; Ihm, SH; Kang, JG; Kim, CS; Kim, SH; Lee, SJ; Yoo, HJ | 1 |
| Lin, W; Liu, BL; Pan, HL; Zhang, YQ | 1 |
| Blassl, C; Djuzenova, CS; Flentje, M; Günther, N; Katzer, A; Kuger, S; Niewidok, N; Polat, B; Roloff, K; Sukhorukov, VL | 1 |
| Aszalos, A; Cardarelli, C; Forte, R; Gottesman, MM; Kozar, M; Liang, XJ; Taylor, B; Wang, PC; Yin, JJ; Zhou, JW | 1 |
| Bleichrodt, RP; Boerman, OC; Goldenberg, DM; Hendriks, T; Koppe, MJ; Oyen, WJ; Verhofstad, AA | 1 |
| Kitamura, T; Matsuura, M; Mutoh, M; Niho, N; Sato, H; Sugimura, T; Takahashi, M; Wakabayashi, K | 1 |
| Aherne, W; Barril, X; Box, G; Boxall, F; Boxall, K; Brough, PA; Cansfield, JE; Cheung, KM; de Haven Brandon, A; Drysdale, MJ; Dymock, B; Eccles, SA; Finch, H; Gowan, S; Hayes, A; Howes, R; Hubbard, RE; James, K; Jones, K; Kalusa, A; Martins, V; Massey, A; Matthews, TP; McDonald, E; Patterson, L; Pearl, L; Prodromou, C; Raynaud, FI; Rowlands, M; Sharp, SY; Surgenor, A; Urban, F; Valenti, M; Webb, P; Wood, M; Workman, P; Wright, L | 1 |
| Cooney, DA; Kensler, TW; Reck, LJ | 1 |
9 other study(ies) available for isoxazoles and Carcinoma
| Article | Year |
|---|---|
HSP90 inhibitor NVP-AUY922 induces cell apoptosis by disruption of the survivin in papillary thyroid carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma; Carcinoma, Papillary; Cell Line, Tumor; Dose-Response Relationship, Drug; Down-Regulation; HSP90 Heat-Shock Proteins; Humans; Inhibitor of Apoptosis Proteins; Isoxazoles; Resorcinols; Signal Transduction; Survivin; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2017 |
The dipeptidyl peptidase-IV inhibitor gemigliptin alone or in combination with NVP-AUY922 has a cytotoxic activity in thyroid carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma; Cell Line, Tumor; Cell Survival; Dipeptidyl-Peptidase IV Inhibitors; Drug Synergism; Flow Cytometry; Humans; Isoxazoles; Piperidones; Pyrimidines; Resorcinols; Signal Transduction; Thyroid Neoplasms | 2017 |
Modulation of Nav1.8 by Lysophosphatidic Acid in the Induction of Bone Cancer Pain.
Topics: Animals; Biophysics; Bone Neoplasms; Cancer Pain; Carcinoma; Disease Models, Animal; Electric Stimulation; Enzyme Inhibitors; Female; Ganglia, Spinal; Gene Expression Regulation, Neoplastic; Hyperalgesia; Isoxazoles; Lysophospholipids; Membrane Potentials; NAV1.8 Voltage-Gated Sodium Channel; Neurons; Pain Measurement; Patch-Clamp Techniques; Propionates; Rats; Rats, Sprague-Dawley; Receptors, Lysophosphatidic Acid | 2016 |
Hsp90 inhibitor NVP-AUY922 enhances radiation sensitivity of tumor cell lines under hypoxia.
Topics: Carcinoma; CDC2 Protein Kinase; Cell Cycle; Cell Hypoxia; Cell Line, Tumor; Cyclin-Dependent Kinase 4; DNA Damage; Glioblastoma; Histones; HSP70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Lung Neoplasms; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-raf; Radiation-Sensitizing Agents; Radiation, Ionizing; Resorcinols | 2012 |
Changes in biophysical parameters of plasma membranes influence cisplatin resistance of sensitive and resistant epidermal carcinoma cells.
Topics: Carcinoma; Cell Division; Cell Line, Tumor; Cell Membrane; Cisplatin; Clone Cells; Cyclic N-Oxides; Drug Resistance, Neoplasm; Fatty Acids; HeLa Cells; Humans; Isoxazoles; Membrane Fluidity; Membrane Lipids; Membrane Potentials; Membrane Proteins; Neoplasms; Potassium Channels; Pyrimidinones | 2004 |
Combination therapy using the cyclooxygenase-2 inhibitor Parecoxib and radioimmunotherapy in nude mice with small peritoneal metastases of colonic origin.
Topics: Animals; Antibodies, Monoclonal; Carcinoma; Colonic Neoplasms; Cyclooxygenase Inhibitors; Iodine Radioisotopes; Isoxazoles; Male; Maximum Tolerated Dose; Mice; Mice, Inbred BALB C; Mice, Nude; Peritoneal Neoplasms; Radioimmunotherapy; Survival; Tissue Distribution; Transplantation, Heterologous | 2006 |
Suppression of azoxymethane-induced colon cancer development in rats by a cyclooxygenase-1 selective inhibitor, mofezolac.
Topics: Animals; Azoxymethane; Carcinoma; Colonic Neoplasms; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Isoxazoles; Male; Membrane Proteins; Rats; Rats, Inbred F344 | 2006 |
NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis.
Topics: Animals; Antineoplastic Agents; Carcinoma; Cell Cycle; Cell Division; Female; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Mice; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; Resorcinols; Transplantation, Heterologous | 2008 |
Therapeutic effects of acivicin and N-(phosphonacetyl)-L-aspartic acid in a biochemically designed trial against a N-(phosphonacetyl)-L-aspartic acid-resistant variant of the Lewis lung carcinoma.
Topics: Animals; Aspartate Carbamoyltransferase; Aspartic Acid; Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing); Carcinoma; Drug Therapy, Combination; Glycine; Isoxazoles; Ligases; Lung Neoplasms; Neoplasms, Experimental; Organophosphorus Compounds; Oxazoles; Phosphonoacetic Acid; Pyrimidines; Rats | 1981 |